Turkey joins the Horizon Europe, Erasmus+ and Solidarity Corps programmes
The Commission and Turkey signed three agreements granting association status to EU programmes for the period 2021-2027
vision-research.eu - The Gateway to European Vision Research
You are here: vision-research.eu » News
News
Mitomycin C increases corneal haze after corneal crosslinking
Shady Awwad, MD, discusses how the application of mitomycin C after corneal crosslinking does not prevent development of corneal haze after the procedure and actually contributes to development of more corneal haze.
Optimism Health Group Expands its Footprint with VisionCall acquisition
Optimism Health Group, a healthcare investment business, has recently completed the acquisition of VisionCall, the UK's leading provider of eye care services in care homes. The acquisition came in line with Optimism’s plans to expand its footprint in the fast-growing market for healthcare products and clinical services to older people.
DED in American veterans
earLab Corp. and MellingMedical are teaming up to empower physicians to more effectively diagnose dry eye disease (DED) among veterans. "We are excited to bring osmolarity testing to America's veterans and help support their patient care and therapy decisions," Chris Melling, founder and CEO of MellingMedical, said in a statement.
Eye cancer culprit
Researchers have identified a molecular mechanism that drives the progression of uveal melanoma (UM), an often lethal eye cancer in adults. The study’s results were published in the journal Nature Communications1 and might offer an opportunity to develop treatments for earlier suppression of a lethal type of tumor that spreads to other parts of the body.
World Council of Optometry’s Online Source for Myopia Management Goes Live
The World Council of Optometry (WCO) and CooperVision, one of the world’s myopia category leaders, have jointly developed an online source that provides several approaches and assets for eye care experts to incorporate a standard of care for myopia management into practice.
Five dimensions of age-related macular degeneration provide new insight
A new study - published in Investigative Ophthalmology and Visual Science from University of Alabama at Birmingham researchers - suggests that linking to a fifth dimension for molecules and affected cells could help define new therapeutic strategies for those suffering from age-related macular degeneration.
Companies announce eye care collaboration
AbbVie and REGENXBIO announced a strategic partnership to develop and commercialize RGX-314, an investigational gene therapy for wet age-related macular degeneration, diabetic retinopathy and other chronic retinal diseases.
India Provides Free Eye Examination Through Mobile Vision Centers
Sightsavers – in participation with SBI Capital Markets - have jointly set up a total of three mobile vision centers in the urban cities of India, namely Chennai, Kolkata, and Pune to provide primary eye care examination for the people with low financial income, according to a news covered by the local media.
Preprint advocates must also fight for research integrity
Efforts to share research with the public must include mechanisms to prevent harm resulting from low-quality work.
Apellis receives mixed results in two Phase 3 studies
Despite varied results, the company will submit a New Drug Application for pegcetacoplan for geographic atrophy to the FDA early next year.
Stop undervaluing smaller institutions
Far from being inferior, smaller universities can outstrip elite ones in research training and promoting inclusivity.
Orbital lymphoma: masquerading as involutional ptosis
Unilateral ptosis can be the first symptom related to other causes that are traumatic, myogenic, neurogenic, or mechanical in nature.
A breakthrough in retinoblastoma treatment using a light-triggered drug release system
Researchers at LKS Faculty of Medicine, The University of Hong Kong (HKUMed) and collaborators from the School of Basic Medical Sciences, Fudan University, Shanghai, have developed an 'intravenous injection plus light-triggered intraocular drug release' strategy to achieve drug accumulation in retinoblastoma.
Horizon Therapeutics enrolls first patient in TEPEZZA study for chronic TED
Horizon Therapeutics announced Tuesday the enrollment of the first patient in its Phase 4 clinical trial analyzing TEPEZZA® for the treatment of thyroid eye disease.
vision-research.eu is kindly supported by ROCHE
Home | Contact | Sitemap | Data protection declaration | Imprint | © 2022 European Vision Institute EEIG, Belgium | info@vision-research.eu